Summary: Disney, Macy's and Green Mountain Coffee Roasters are in focus in earnings news and Pfizer gets the greenlight from the FDA for a breast cancer drug two months early. Disney posted better than expected earnings and higher revenue in its latest quarter thanks to strong topline numbers from its TV networks and sales of paraphernalia associated with the animated movie Frozen. Macy's is a stock to watch today as it raised its outlook for the year and plans to buy BlueMercury for $210 million in cash. The FDA has granted early approval of Pfizer's drug used to treat advanced stage breast cancer. The approval of Inbrance came two months early. Pfizer needs some big-selling new drugs to boost its earnings, following patent expirations on many of its biggest brands and a relatively thin supply of promising drugs in late-stage trials. Pfizer said the drug is available to order immediately through specialty pharmacies. Keurig Green Mountain Coffee Roasters turns in first quarter earnings results today. KeyBank Capital Markets reiterates its BUY rating on GMCR with a $175 price target. Sales of single K Cups versus sales of brewers are expected to drive numbers.
